The Formulary Management Expert Committee (FMEC) recommends that naloxegol be reimbursed for the treatment of opioid-induced constipation (OIC) in adult patients with either cancer pain or noncancer pain, who have inadequate response to laxative(s) provided certain conditions are met.
